Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Yahoo! Finance
a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer. Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer” Abstract Number: Poster Session: Gastrointestinal Cancer – Colorectal and Anal Poster Board: Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m.
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]Seeking Alpha
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZNTL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.MarketBeat
ZNTL
Earnings
- 11/10/25 - Beat
ZNTL
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form SCHEDULE
- 12/15/25 - Form 8-K
- ZNTL's page on the SEC website